ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has revealed a major contract acquisition with Artios Pharma.
ImmuPharma PLC (AIM:IMM, OTC:IMMPF) plans to focus this year on advancing Lupuzor, its lupus treatment, into phase II/III clinical trials later in the year.
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a liquid biopsy company, announced that it achieved a significant milestone in 2022, with clearance from the US Food & Drug Administration (FDA) and
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has signed an agreement with Crescendo Biologics, a clinical-stage immuno-oncology company, to offer its advanced Portrait Flex Assay, a liquid biopsy tool, for a
Sareum submits Clinical Trial Authorisation application to UK MHRA for development of TYK2/JAK1 inhibitor SDC-1801 and provides an Operational Update
CTCs, CTC clusters and CTC-WBC clusters harvested using Parsortix were more numerous and more aggressive in initiating metastasis during sleep
PARSORTIX ENABLES MOLECULAR CHARACTERISATION OF CTCS ISOLATED FROM FROZEN SAMPLES IN PATIENTS WITH NON-SMALL CELL LUNG CANCER AND SARCOMA
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2021 (the
Data confirms positive readout from P140 PK study
MiNK Therapeutics secured its Nasdaq spot Friday with a $40 million initial public offer. This was to allow MiNK Therapeutics to move its lead candidate through phase I trials in
On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the exploration and development of foralumab as a lymphodepletion agent to